Cyclerion Therapeutics, Inc. (CYCN)
| Market Cap | 87.86M |
| Revenue (ttm) | 2.30M |
| Net Income (ttm) | -77.80M |
| Shares Out | 33.96M |
| EPS (ttm) | -2.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $2.46 |
| Previous Close | $2.58 |
| Change ($) | -0.13 |
| Change (%) | -4.84% |
| Day's Open | 2.57 |
| Day's Range | 2.31 - 2.58 |
| Day's Volume | 348,235 |
| 52-Week Range | 2.18 - 8.96 |
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive fun...
Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company's advancement of therapeutic pipeline candidates
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseas...
Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor
Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative di...
A second midstage failure is hurting the biotech's stock price today.
Showed significant i mprovements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases
Study results do not support further internal development Study results do not support further internal development
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sG...
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today...
Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
- IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively -
- Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease -
CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today...
– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –
– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases –
The company evaluated praliciguat in 2 diseases, diabetic nephropathy and HFpEF, which are very complex and difficult-to-treat.
A double clinical trial failure sends the biotech’s shares down.
Shares of Cyclerion Therapeutics Inc. plummeted 71% toward a record low Wednesday, to pace all premarket losers, after the biopharmaceutical company said a Phase 2 trial of its diabetes treatment missed...
About CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cy... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol CYCN |
Financial Performance
In 2020, CYCN's revenue was $2.30 million, a decrease of -49.06% compared to the previous year's $4.51 million. Losses were -$77.80 million, -36.75% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for CYCN stock is "Hold" and the 12-month stock price forecast is 4.00.